Exosomal formulation of anthocyanidins against multiple cancer types

Cancer Letters

Volumn 393, Issue , 2017, Pages 94-102

  Munagala, Radha ^a,b   Aqil, Farrukh ^a,b   Jeyabalan, Jeyaprakash ^a   Agrawal, Ashish K ^a   Mudd, Ashley M ^b   Kyakulaga, Al Hassan ^b   Singh, Inder P ^c   Vadhanam, Manicka V ^a   Gupta, Ramesh C ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Anthocyanidins; Anti cancer; Anti inflammatory; Drug delivery; Milk exosomes

Indexed keywords

AGLYCONE ANTHOCYANIDIN DERIVATIVE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; ANTHOCYANIN; ANTIINFLAMMATORY AGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BILBERRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; EXOSOME; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOUSE; MTT ASSAY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; A-549 CELL LINE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HCT 116 CELL LINE; MALE; MCF-7 CELL LINE; MILK; NUDE MOUSE; ORAL DRUG ADMINISTRATION; TIME FACTOR; TOXICITY; TUMOR VOLUME;

A549 CELLS; ADMINISTRATION, ORAL; ANIMALS; ANTHOCYANINS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; EXOSOMES; FEMALE; HCT116 CELLS; HUMANS; MALE; MCF-7 CELLS; MICE, NUDE; MILK; NANOPARTICLES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014479512     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.02.004     Document Type: Article

References (70)

1. [1] Oliveira, H., Wu, N., Zhang, Q., Wang, J., Oliveira, J., de Freitas, V., et al. Bioavailability studies and anticancer properties of malvidin based anthocyanins, pyranoanthocyanins and non-oxonium derivatives. Food Funct. 7 (2016), 2462–2468.
2. [2] Lila, M.A., Burton-Freeman, B., Grace, M., Kalt, W., Unraveling anthocyanin bioavailability for human health. Annu. Rev. Food Sci. Technol. 7 (2016), 375–393.
3. [3] McGhie, T.K., Walton, M.C., The bioavailability and absorption of anthocyanins: towards a better understanding. Mol. Nutr. Food Res. 51 (2007), 702–713.
4. [4] Oehlke, K., Adamiuk, M., Behsnilian, D., Graf, V., Mayer-Miebach, E., Walz, E., et al. Potential bioavailability enhancement of bioactive compounds using food-grade engineered nanomaterials: a review of the existing evidence. Food & Funct. 5 (2014), 1341–1359.
5. [5] Siddiqui, I.A., Adhami, V.M., Bharali, D.J., Hafeez, B.B., Asim, M., Khwaja, S.I., et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 69 (2009), 1712–1716.
6. [6] Siddiqui, I.A., Sanna, V., Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy. Mol. Nutr. Food Res. 60 (2016), 1330–1341.
7. [7] Yallapu, M.M., Jaggi, M., Chauhan, S.C., Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 17 (2012), 71–80.
8. [8] Ranjan, A.P., Mukerjee, A., Helson, L., Gupta, R., Vishwanatha, J.K., Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Res. 33 (2013), 3603–3609.
9. [9] Khan, N., Bharali, D.J., Adhami, V.M., Siddiqui, I.A., Cui, H., Shabana, S.M., et al. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 35 (2014), 415–423.
10. [10] Wang, D., Taylor, E.W., Wang, Y., Wan, X., Zhang, J., Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. Int. J. Nanomed. 7 (2012), 1711–1721.
11. [11] Shao, J., Li, X., Lu, X., Jiang, C., Hu, Y., Li, Q., et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B Biointerfaces 72 (2009), 40–47.
12. [12] Caddeo, C., Teskac, K., Sinico, C., Kristl, J., Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int. J. Pharm. 363 (2008), 183–191.
13. [13] Yang, F., Jin, C., Jiang, Y., Li, J., Di, Y., Ni, Q., et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat. Rev. 37 (2011), 633–642.
14. [14] Sadasivam, M., Avci, P., Gupta, G.K., Lakshmanan, S., Chandran, R., Huang, Y.Y., et al. Self-assembled liposomal nanoparticles in photodynamic therapy. Eur. J. Nanomed, 5, 2013, 10.1515/ejnm-2013-0010.
15. [15] Çağdaş, M., Sezer, A.D., Bucak, S., Liposomes as Potential Drug Carrier Systems for Drug Delivery, Application of Nanotechnology in Drug Delivery. 2014, InTech, 10.5772/58459.
16. [16] Feng, L., Mumper, R.J., A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 334 (2013), 157–175.
17. [17] Kooijmans, S.A., Vader, P., van Dommelen, S.M., van Solinge, W.W., Schiffelers, R.M., Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed. 7 (2012), 1525–1541.
18. [18] Lakhal, S., Wood, M.J., Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. Bioessays 33 (2011), 737–741.
19. [19] Munagala, R., Aqil, F., Jeyabalan, J., Gupta, R.C., Bovine milk-derived exosomes for drug delivery. Cancer Lett. 371 (2016), 48–61.
20. [20] Jeyabalan, J., Aqil, F., Munagala, R., Annamalai, L., Vadhanam, M.V., Gupta, R.C., Chemopreventive and therapeutic activity of dietary blueberry against estrogen-mediated breast cancer. J. Agric. Food Chem. 62 (2014), 3963–3971.
21. [21] Kausar, H., Jeyabalan, J., Aqil, F., Chabba, D., Sidana, J., Singh, I.P., et al. Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cells. Cancer Lett. 325 (2012), 54–62.
22. [22] Ravoori, S., Vadhanam, M.V., Aqil, F., Gupta, R.C., Inhibition of estrogen-mediated mammary tumorigenesis by blueberry and black raspberry. J. Agric. Food Chem. 60 (2012), 5547–5555.
23. [23] Aiyer, H.S., Gupta, R.C., Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism. Cancer Prev. Res. (Phila) 3 (2010), 727–737.
24. [24] Aiyer, H.S., Srinivasan, C., Gupta, R.C., Dietary berries and ellagic acid diminish estrogen-mediated mammary tumorigenesis in ACI rats. Nutr. Cancer 60 (2008), 227–234.
25. [25] Adams, L.S., Phung, S., Yee, N., Seeram, N.P., Li, L., Chen, S., Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res. 70 (2010), 3594–3605.
26. [26] Seeram, N.P., Adams, L.S., Zhang, Y., Lee, R., Sand, D., Scheuller, H.S., et al. Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J. Agric. Food Chem. 54 (2006), 9329–9339.
27. [27] Kanaya, N., Adams, L., Takasaki, A., Chen, S., Whole blueberry powder inhibits metastasis of triple negative breast cancer in a xenograft mouse model through modulation of inflammatory cytokines. Nutr. Cancer 66 (2014), 242–248.
28. [28] Skrovankova, S., Sumczynski, D., Mlcek, J., Jurikova, T., Sochor, J., Bioactive compounds and antioxidant activity in different types of berries. Int. J. Mol. Sci. 16 (2015), 24673–24706.
29. [29] Yousuf, B., Gul, K., Wani, A.A., Singh, P., Health benefits of anthocyanins and their encapsulation for potential use in food systems: a review. Crit. Rev. Food Sci. Nutr. 56 (2016), 2223–2230.
30. [30] Welch, C.R., Wu, Q., Simon, J.E., Recent advances in anthocyanin analysis and characterization. Curr. Anal. Chem. 4 (2008), 75–101.
31. [31] Kresty, L.A., Mallery, S.R., Stoner, G.D., Black raspberries in cancer clinical trials: past, present and future. J. Berry Res. 6 (2016), 251–261.
32. [32] Montrose, D.C., Horelik, N.A., Madigan, J.P., Stoner, G.D., Wang, L.S., Bruno, R.S., et al. Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis 32 (2011), 343–350.
33. [33] Stoner, G.D., Sardo, C., Apseloff, G., Mullet, D., Wargo, W., Pound, V., et al. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J. Clin. Pharmacol. 45 (2005), 1153–1164.
34. [34] Kresty, L.A., Frankel, W.L., Hammond, C.D., Baird, M.E., Mele, J.M., Stoner, G.D., et al. Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: interim results show berries modulate markers of oxidative stress in Barrett's esophagus patients. Nutr. Cancer 54 (2006), 148–156.
35. [35] Kresty, L.A., Fromkes, J.J., Frankel, W.L., Hammond, C.D., Seeram, N.P., Baird, M., et al. A phase I pilot study evaluating the beneficial effects of black raspberries in patients with Barrett's esophagus. Oncotarget, 2016, 10.18632/oncotarget.10457.
36. [36] Mallery, S.R., Tong, M., Shumway, B.S., Curran, A.E., Larsen, P.E., Ness, G.M., et al. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clin. Cancer Res. 20 (2014), 1910–1924.
37. [37] Shumway, B.S., Kresty, L.A., Larsen, P.E., Zwick, J.C., Lu, B., Fields, H.W., et al. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin. Cancer Res. 14 (2008), 2421–2430.
38. [38] Stoner, G.D., Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev. Res. (Phila) 2 (2009), 187–194.
39. [39] Fang, J., Bioavailability of anthocyanins. Drug Metab. Rev. 46 (2014), 508–520.
40. [40] Kay, C.D., Aspects of anthocyanin absorption, metabolism and pharmacokinetics in humans. Nutr. Res. Rev. 19 (2006), 137–146.
41. [41] Smeriglio, A., Barreca, D., Bellocco, E., Trombetta, D., Chemistry, pharmacology and health benefits of anthocyanins. Phytother. Res. 30 (2016), 1265–1286.
42. [42] Hassimotto, N.M., Genovese, M.I., Lajolo, F.M., Absorption and metabolism of cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus nigra L.) in rats. Nutr. Res. 28 (2008), 198–207.
43. [43] Talavera, S., Felgines, C., Texier, O., Besson, C., Gil-Izquierdo, A., Lamaison, J.L., et al. Anthocyanin metabolism in rats and their distribution to digestive area, kidney, and brain. J. Agric. Food Chem. 53 (2005), 3902–3908.
44. [44] Day, A.J., Canada, F.J., Diaz, J.C., Kroon, P.A., McLauchlan, R., Faulds, C.B., et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett. 468 (2000), 166–170.
45. [45] Aqil, F., Gupta, A., Munagala, R., Jeyabalan, J., Kausar, H., Sharma, R.J., et al. Antioxidant and antiproliferative activities of anthocyanin/ellagitannin-enriched extracts from Syzygium cumini L. (Jamun, the Indian Blackberry). Nutr. Cancer 64 (2012), 428–438.
46. [46] Afaq, F., Syed, D.N., Malik, A., Hadi, N., Sarfaraz, S., Kweon, M.H., et al. Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis. J. Invest Dermatol 127 (2007), 222–232.
47. [47] Hafeez, B.B., Siddiqui, I.A., Asim, M., Malik, A., Afaq, F., Adhami, V.M., et al. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Res. 68 (2008), 8564–8572.
48. [48] Seeram, N.P., Zhang, Y., Nair, M.G., Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins. Nutr. Cancer 46 (2003), 101–106.
49. [49] Aqil, F., Kausar, H., Agrawal, A.K., Jeyabalan, J., Kyakulaga, A.-H., Munagala, R., et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp. Mol. Pathol. 101 (2016), 12–21.
50. [50] Gupta, R.C. (2015). Method for isolation of bulk anthocyanidins and other bioactives. Patent number - US8987481 B1.
51. [51] Munagala, R., Kausar, H., Munjal, C., Gupta, R.C., Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 32 (2011), 1697–1705.
52. [52] Paul, P.K., Gupta, S.K., Bhatnagar, S., Panguluri, S.K., Darnay, B.G., Choi, Y., et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191 (2010), 1395–1411.
53. [53] Hoque, M., Dave, S., Gupta, P., Saleemuddin, M., Oleic acid may Be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action. PLoS One, 8, 2013, e68390.
54. [54] Liskova, K., Kelly, A.L., O'Brien, N., Brodkorb, A., Effect of denaturation of alpha-lactalbumin on the formation of BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). J. Agric. Food Chem. 58 (2010), 4421–4427.
55. [55] Rammer, P., Groth-Pedersen, L., Kirkegaard, T., Daugaard, M., Rytter, A., Szyniarowski, P., et al. BAMLET activates a lysosomal cell death program in cancer cells. Mol. Cancer Ther. 9 (2010), 24–32.
56. [56] Lawrence, T., The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol., 1, 2009, a001651.
57. [57] Desai, K.G., Olsen, K.F., Mallery, S.R., Stoner, G.D., Schwendeman, S.P., Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins. Pharm. Res. 27 (2010), 628–643.
58. [58] Celli, G.B., Brooks, M.S.L., Ghanem, A., Development and evaluation of a novel alginate-based in situ gelling system to modulate the release of anthocyanins. Food Hydrocoll. 60 (2016), 500–508.
59. [59] Arroyo-Maya, I.J., McClements, D.J., Biopolymer nanoparticles as potential delivery systems for anthocyanins: fabrication and properties. Food Res. Int. 69 (2015), 1–8.
60. [60] Idham, Z., Muhamad, I.I., Sarmidi, M.R., Degradation kinetics and color stability of spray-dried encapsulated anthocyanins from Hibiscus Sabdariffa L. J. Food Process Eng. 35 (2012), 522–542.
61. [61] Berg, S., Bretz, M., Hubbermann, E.M., Schwarz, K., Influence of different pectins on powder characteristics of microencapsulated anthocyanins and their impact on drug retention of shellac coated granulate. J. Food Eng. 108 (2012), 158–165.
62. [62] Batrakova, E.V., Kim, M.S., Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control Release 219 (2015), 396–405.
63. [63] Ha, D., Yang, N., Nadithe, V., Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6 (2016), 287–296.
64. [64] Johnsen, K.B., Gudbergsson, J.M., Skov, M.N., Pilgaard, L., Moos, T., Duroux, M., A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846 (2014), 75–87.
65. [65] Ren, J., He, W., Zheng, L., Duan, H., From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater. Sci. 4 (2016), 910–921.
66. [66] Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G.J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 (2014), 2383–2390.
67. [67] Jang, S.C., Kim, O.Y., Yoon, C.M., Choi, D.S., Roh, T.Y., Park, J., et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7 (2013), 7698–7710.
68. [68] Kim, M.S., Haney, M.J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N.L., et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12 (2016), 655–664.
69. [69] Saari, H., Lazaro-Ibanez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., Yliperttula, M., Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J. Control Release 220 (2015), 727–737.
70. [70] Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18 (2010), 1606–1614.